Dendritic cell-based vaccine efficacy: aiming for hot spots
Many approaches for cancer immunotherapy have targeted dendritic cells (DC), directly or indirectly, for the induction of antitumor immune responses. DC-based vaccines have been developed using a wide variety of ex vivo DC culture conditions, antigen source and loading strategies, maturation agents...
Main Authors: | Gabriela Andrea Pizzurro, María Marcela eBarrio |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2015-03-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2015.00091/full |
Similar Items
-
Recent Advances in Experimental Dendritic Cell Vaccines for Cancer
by: Ivan Y. Filin, et al.
Published: (2021-09-01) -
Stable contacts of naïve CD4 T cells with migratory dendritic cells are ICAM-1-dependent but dispensable for proliferation in vivo
by: Stav Kozlovski, et al.
Published: (2019-01-01) -
Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting
by: Alexey V. Baldin, et al.
Published: (2020-03-01) -
Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines
by: Lien eVandenberk, et al.
Published: (2016-01-01) -
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
by: Linda M. Liau, et al.
Published: (2018-05-01)